A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer.
Saved in:
| Title: | A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. |
|---|---|
| Authors: | Davis SL; University of Colorado Cancer Center, Aurora, Colorado, USA sarah.davis@ucdenver.edu., Eckhardt SG; The University of Texas at Austin Dell Medical School, Austin, Texas, USA., Diamond JR; University of Colorado Cancer Center, Aurora, Colorado, USA., Messersmith WA; University of Colorado Cancer Center, Aurora, Colorado, USA., Dasari A; MD Anderson Cancer Center, Houston, Texas, USA., Weekes CD; Massachusetts General Hospital, Boston, Massachusetts, USA., Lieu CH; University of Colorado Cancer Center, Aurora, Colorado, USA., Kane M; University of Colorado Cancer Center, Aurora, Colorado, USA., Choon Tan A; University of Colorado Cancer Center, Aurora, Colorado, USA., Pitts TM; University of Colorado Cancer Center, Aurora, Colorado, USA., Leong S; University of Colorado Cancer Center, Aurora, Colorado, USA. |
| Source: | The oncologist [Oncologist] 2018 Dec; Vol. 23 (12), pp. 1409-e140. Date of Electronic Publication: 2018 Aug 23. |
| Publication Type: | Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1549-490X |
|---|---|
| DOI: | 10.1634/theoncologist.2018-0315 |
